Objectives: The primary objective of this randomized trial was to compare thoracic epidural analgesia (TEA) to intravenous patient-controlled analgesia (IV-PCA) for pain control over the first 48 hours after hepatopancreatobiliary (HPB) surgery. Secondary endpoints were patient-reported outcomes, total narcotic utilization, and complications. Background: Although adequate postoperative pain control is critical to patient and surgeon success, the optimal analgesia regimen in HPB surgery remains controversial. Methods: Using a 2.5:1 randomization strategy, 140 patients were randomized to TEA (N ¼ 106) or intravenous patient-controlled analgesia (N ¼ 34). Patient-reported pain was measured on a Likert scale (0-10) at standard time intervals. Cumulative pain area under the curve was determined using the trapezoidal method. Results: Between the study groups key demographic, comorbidity, clinical, and operative variables were equivalently distributed. The median area under the curve of the postoperative time 0-to 48-hour pain scores was lower in the TEA group (78.6 vs 105.2 pain-hours, P ¼ 0.032) with a 35% reduction in patients experiencing !7/10 pain (43% vs 62%, P ¼ 0.07). Patient-reported outcomes and total opiate use further supported the benefit of TEA on patient experience. Anesthesia-related events requiring change in analgesic therapy were comparable (12.2% vs 2.9%, respectively, P ¼ 0.187). Grade 3 or higher surgical complications (6.6% vs 9.4%), median length of stay (6 days vs 6 days), readmission (1.9% vs 3.1%), and return to the operating room (0.9% vs 3.1%) were similar (all P > 0.05). There were no mortalities in either group. Conclusions: In major HPB surgery, TEA provides a superior patient experience through improved pain control and less narcotic use, without increased length of stay or complications.
A s the safety of hepatopancreaticobiliary surgery has improved, the practice has grown in number of cases and complexity. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Compared to traditional open surgical procedures, minimally invasive laparoscopic surgery has led to decreased postoperative pain. [15] [16] [17] In the majority of hepatic and pancreatic resections, a minimally invasive approach is, however, not technically feasible, and postoperative pain continues to be poorly controlled despite high narcotic doses, with adverse impact on patient experience and patient outcomes. 18 Inadequate pain control after open abdominal procedures may have both primary and secondary impacts on patient outcomes. In the initial postoperative period, inadequate pain control contributes to the neuroendocrine stress response, increased complications, and prolonged length of stay. 19, 20 These adverse initial outcomes can delay overall recovery, limiting the patient's ability to return to normal levels of function, and in the case of patients with cancer, the ability to return to intended oncologic therapy. 21 This is particularly relevant in hepatopancreatobiliary (HPB) surgery, in which procedures can be disabling and most patients undergo oncologic resection. Effective pain control is, therefore, imperative in these patients. Yet, the best modality for pain control after hepatopancreaticobiliary resection remains unclear.
Two of the most common analgesic modalities used after inpatient abdominal surgery are thoracic epidural analgesia (TEA) with local anesthetic agents and/or narcotics, and intravenous patientcontrolled analgesia (IV-PCA) using narcotics. Multiple nonrandomized comparisons have been reported; however, relatively few level 1 data from randomized trials are available. [22] [23] [24] [25] [26] [27] [28] Currently, the advantages and disadvantages between these 2 strategies continue to be debated, and the most effective strategy has not been determined. The objective of this randomized controlled trial (RCT) was to compare the efficacy of pain control and safety between TEA and IV-PCA.
METHODS

Patients
The present study was conducted between February 2012 and September 2016 at the University of Texas MD Anderson Cancer Center. The Ethical Committee on Clinical Investigation approved this RCT and it was registered in accordance with ClinicalTrials.gov (NCT01438476). A written informed consent was obtained before surgery from all participating patients.
Eligible patients were 18 years of age or older undergoing liver or pancreatic resection for malignancy. Both minor and major hepatectomies were included in the RCT. Major hepatectomy was defined by the Brisbane 2000 terminology as resection of 3 or more Couinaud segments. [29] [30] [31] [32] All patients were required to have adequate coagulation function within 30 days of surgery, defined as platelet count 100,000/mL or more, INR 1.5 or less, and partial thromboplastin time 40 seconds or less. Patients with fever, evidence of infection, or other coexisting medical conditions that would preclude epidural placement were excluded. Other exclusions included history of chronic pain, longterm narcotic use, history of anaphylaxis to local anesthetics or narcotics, previous or current neurologic disease affecting the hemithorax or below, bleeding diathesis or coagulopathy, major open abdominal/thoracic surgery in the previous 30 days under general anesthesia (except total intravenous anesthesia), ongoing use or planned perioperative use of anticoagulants [not including deep vein thrombosis (DVT) prophylaxis]. Patients with educational, psychiatric (untreated or poorly controlled schizophrenia, major depression, or bipolar disorder), or communication (language) barriers that would preclude accurate assessment of postoperative pain and/or ability to answer questions about pain were not eligible.
Randomization
After providing written informed consent, patients undergoing resection were randomly assigned on the morning of surgery to the TEA or IV-PCA group with a 2.5 TEA: 1 IV-PCA randomization strategy.
Analgesic Regimens
All patients randomized to TEA had a thoracic epidural catheter placed preoperatively in the holding area or the operating room. Epidural catheters were placed between the 5th and 10th thoracic interspinous levels using standard technique according to institutional practices. After a negative test dose, a bolus of 10 mg/kg of epidural hydromorphone (maximum of 1 mg) was administered before securing the catheter. All epidural catheters were tested for correct placement and level of block was documented. Before surgical incision, 3 to 10 mL of 2% lidocaine was administered incrementally through the epidural catheter to establish a block. Continuous analgesia was subsequently achieved with an epidural infusion of bupivacaine 0.075% and hydromorphone 5 mg/mL at 5 to 8 mL/h. Secondary alternatives to hydromorphone were fentanyl and bupivacaine. Infusion rates on the surgical floor were 5 to 8 mL/h with an added patient controlled epidural analgesia dose of 3 mL every 10 minutes as needed (not to exceed 6 mL/h). Infusions and catheters were discontinued when patients were successfully tolerating a diet (or tube feeds) and could be safely transitioned to oral/enteral analgesics.
For patients randomized to the IV-PCA group, intraoperative intravenous narcotics were titrated by the anesthesia team until the patient was awake and alert in the postanesthesia care unit, and then IV-PCA infusion was initiated. Hydromorphone was the opioid of choice unless the patient had allergic reaction or other contraindications. Secondary alternatives included fentanyl or morphine. The initial recommended starting dose settings included: no basal rate, 0.2 mg every 10 minutes of demand dosing, and a 0.5 mg nursing bolus every 1 hour as needed for additional pain control.
Adjunctive oral, rectal, or intravenous non-narcotic analgesics (i.e., acetaminophen or nonsteroidal) were used at the discretion of the acute pain service and/or primary surgical team for both the TEA and IV-PCA groups. In cases with inadequate pain control, crossover between arms was permitted, although all patient outcomes were assessed within randomized groups on an intention-to-treat basis.
Study Endpoints
The primary endpoint was the area under the curve (AUC) pain score during the first 48 hours after surgery. Patient-reported pain scores were assessed in both groups with a numeric/visual pain scale (0-10) at multiple time points per day that started immediately in the postoperative care unit and concluded after postoperative day (POD) 5. With pain scores collected at specific time points, an AUC for pain was calculated for the first 48 hours after surgery (AUC 48) using the trapezoidal method. In addition, episodes of severe pain, defined as any pain score response of 7 or greater, were recorded. Secondary study endpoints included patient-reported functional outcomes, narcotic use during the first 5 postoperative days, surgical complications, analgesic-related complications, and length of stay.
To calculate total narcotic use, all medication doses were converted into oral morphine equivalents (OME) using previously reported conversions. 33 When calculating OME, narcotics dosed through the TEA were considered equivalent (1:1) to IV narcotic dosing administered either through intravenous line or IV-PCA.
Surgical and analgesic complication data were collected in real-time and retrospectively graded with the Modified Accordion Severity Grading (MAG) System. 34 Each complication was categorized into its appropriate system: neurology, cardiovascular, pulmonary, gastrointestinal, renal, wound, sepsis, and other. In addition, postoperative bile leak and liver failure were specifically included for analysis using standard definitions. 35, 36 Severe complications were defined as a Modified Accordion Severity Grading System 3-5. All complications were reviewed by 2 surgical oncology department staff members. Intraoperative and postoperative administration of packed red blood cells was considered a transfusion. The postoperative transfusion period included any time after the operation until hospital discharge. For patients with TEA, the Acute Pain Service monitored the epidural site daily for evidence of hematoma, cellulitis, abscess, cerebrospinal fluid leak, and malfunction. Analgesic complication was defined as any event that required a discontinuation of the analgesic modality being used.
Several validated patient-reported outcome tools were administered to further measure pain, satisfaction with pain control, quality of life, and recovery of function. The Short Form (SF)-8 health survey [37] [38] [39] and SF-36 [40] [41] [42] were both administered preoperatively. Approximately 24 hours after surgery, the SF-8 was repeated, whereas the SF-36 was administered near day of hospital discharge. Quality of recovery and patient satisfaction were measured with the Health Outcomes Recovery Survey 43 with daily administration on the first 5 postoperative inpatient days. In this survey, patients were asked ''how satisfied or unsatisfied are you with overall performance of your pain medication?'' This patient satisfaction score was measured on a scale from 1 to 7: 1. very satisfied, 2. somewhat satisfied, 3. slightly satisfied, 4. neither satisfied nor unsatisfied, 5. slightly unsatisfied, 6. somewhat unsatisfied, 7. very unsatisfied.
Data Collection
For all patients, data were prospectively collected in real-time. Variables collected included patient demographics, pain scores, perioperative clinical information, and complications. Patientreported pain assessment began in the post anesthesia care unit by the nursing staff approximately every hour until the patient was transferred to their designated inpatient care units. In the overnight recovery suite and general floor, pain was assessed by nursing staff approximately every 4 hours, whereas in the surgical intensive care unit, pain was assessed by the nursing staff every hour.
Statistical Analysis
The distribution of each continuous variable was summarized by its mean AE standard deviation and/or median with range (R)/ interquartile range (IQR). The distribution of each categorical variable was summarized in terms of its frequency and percentage. Continuous variables were compared between treatment groups by Wilcoxon rank-sum tests, and for the categorical variables, the comparison between treatments was conducted with Fisher exact tests. To assess the relative impact of patient, surgical and analgesia variables on study endpoints, univariate and multivariate regression models were developed. Backward stepwise model selection was used to obtain the final regression model for the primary endpoint of AUC 48. Piecewise polynomial regression was used to characterize mean pain score trends over time with 95% confidence bands representing interval estimators that characterize the extent of uncertainty at significance level 0.05 over the follow-up time domain observed in our study population. AdaptFitOS version 0.62 package was used in R version 3.1.3 to compute the confidence bands. Other statistical analyses were performed using SPSS Statistics 21 (IBM, Armonk, NY). All tests were 2 sided.
RESULTS
During the study period, 178 screened patients were initially eligible for inclusion to the RCT. A consort flow diagram of this RCT is shown in Figure 1 . 44 Among the 178 eligible patients, 38 patients were excluded due to withdrawal of consent, development of exclusion criteria and/or the finding of unresectable disease at surgery. The study concluded with 140 patients eligible for analysis, with 106 patients allocated to the TEA group and 34 patients allocated to the IV-PCA group. Table 1 reports the distribution of patient characteristics, preoperative, and perioperative variables between the TEA and IV-PCA groups. A total of 136 patients had a liver resection and 4 patients had a major pancreas resection (3 pancreaticoduodenectomies and 1 total pancreatectomy). Oncologic indications for resection included colorectal liver metastases (88, 62.9%), cholangiocarcinoma (13, 9.3%), hepatocellular carcinoma (9, 6.4%), gallbladder adenocarcinoma (7, 5%), neuroendocrine tumor (5, 3.6%), and other histologies (17, 12.1%). There were no differences observed in preoperative clinical or perioperative features between TEA and IV-PCA groups.
Patient Characteristics
Primary Endpoint: Postoperative Pain Experience
The median length of time on the study pain control modality was similar between randomized groups (TEA: 4 days, IQR 3-4 days vs IV-PCA: 4 days, IQR 3-5 days, P ¼ 0.597). For all patients, the overall median AUC 48 was 86.4 pain hours (range: 0-267.3). The median AUC 48 was less in patients who had TEA (78.6, R: 0-228.5) versus IV-PCA (105.2, R: 33.9-267.3), P ¼ 0.0322. In addition, fewer patients in the TEA (42.5%) group experienced inadequate pain control compared to those in the IV-PCA (61.8%) group, P ¼ 0.0747. Figure 2 graphically depicts the pain experience in the TEA group when compared to IV-PCA. After adjustment of preoperative 
Postoperative Surgical and Analgesic-related Complications
Among 140 patients, 50 (35.7%) patients experienced a surgical complication, with 10 (7.1%) of these patients experiencing a severe complication. Collectively, there were 1 neurologic, 8 cardiac, 3 respiratory, 5 renal, 14 gastrointestinal, 8 wound, and 7 other complications. For liver-related complications, there were 5 (3.6%) patients with bile leak and 1 (0.7%) patient who had liver failure. There were zero symptomatic DVT events, but 2 patients were diagnosed with pulmonary embolism in the absence of DVT. Comparing TEA and IV-PCA groups, severe surgical complication rates were similar (6.6% vs 9.4%, respectively, P ¼ 0.705). The median peak postoperative bilirubin was 1.4 (R: 0.3-11.8 mg/dL), and the median peak postoperative creatinine was 0.9 (R: 0.1-2.3 mg/dL), with no differences in these values between the study groups. Overall, 2 (1.4%) patients returned to the operating room, and 3 (2.1%) required readmission. The median length of stay was the same between TEA (6 days, IQR: 5-7 days) and IV-PCA (6 days, IQR: 5-7 days), P ¼ 0.957. There were no 90-day mortalities.
Twelve patients experienced an analgesic-related complication that required discontinuation of the original pain control modality. For analgesic-related complications, there was no difference between TEA and IV-PCA (12.2% vs 2.9%, respectively, P ¼ 0.187), and all were less than MAG 3. Two patients with TEA required replacement of the epidural catheter due to catheter migration or malfunction and 2 TEA group patients required change of pain management modality to IV-PCA due to inadequate pain control. In 15 patients, TEA had to be placed on hold for a median time of 2 hours (IQR: 1-3.25 hours) due to hypotension. Among these patients who experienced hypotension with TEA in place, the median peak creatinine was 0.67 mg/dL (IQR: 0.6-0.84 mg/dL) with only 1 patient developing a peak creatinine above 1.5 mg/dL during hospitalization.
Postoperative Narcotic Utilization
The median cumulative OME over the first 5 postoperative days was markedly less in the TEA (155.3 mg, R: 53.43-2747.3 mg) group when compared to IV-PCA (429.8 mg, R: 69.8-1787.5 mg), P < 0.001. In addition, patients in the TEA group required less daily OME for the majority of postoperative days (POD 0-3, all 
Patient-reported Outcomes
The vast majority of patients completed the SF-8 before (TEA: 99.1%; IV-PCA 100%) and after (TEA: 90.1%; IV-PCA 94.1%) surgery. Using this tool, TEA and IV-PCA patients were found to have similar levels of baseline (preoperative) pain (Table 2) , P ¼ 0.468; in contrast, postoperatively, a significantly larger number of patients in the TEA (62.5%) group reported having less than mild pain when compared to the IV-PCA (40.6%) group, P¼0.03 (Table 3 The Health Outcomes Recovery Survey instrument was answered by the majority of patients on each postoperative day (POD 1: 91.4%, POD 2: 88.6%, POD 3 86.4%, POD 4: 82.4%, POD 5 83.3%). This instrument identified greater patient satisfaction with pain control in the TEA group compared to the IV-PCA group (P ¼ 0.022, Fig. 4 ). Further analysis with a mixed effects model to control for covariates identified a strong association between TEA and patient satisfaction with pain control, P ¼ 0.035.
DISCUSSION
As short-term hepatobiliary surgical outcomes have improved, focus is shifting to patient experience and oncologic outcomes. Regarding the important aspect of optimization of perioperative analgesia, the hepatobiliary surgical literature includes a number of nonrandomized studies suggesting that TEA is a more complex analgesic regimen that, when inadequately supported at the bedside, can be associated with safety concerns including hypotension and a need for excessive fluid and blood product administration. [22] [23] [24] [25] [26] [27] [28] The efficacy of the pain control associated with this modality has been observed to be as good or better than intravenous narcotics. One small randomized trial, comparing TEA to IV-PCA, demonstrated superior pain control in the epidural arm but with a longer time to fulfill discharge criteria. Furthermore, analgesia in the PCA arm was augmented with continuous infiltration of local anesthetic using wound catheters and patient recovery beyond length of stay was not measured. 45 Given the lack of randomized data on this important topic, it is clear that further investigation was warranted.
In the present study a patient cohort, treated mainly with open liver resection, was randomized to TEA compared with IV-PCA with a primary endpoint of pain score AUC over the first 48 hours after surgery, and secondary endpoints of narcotic usage and patientreported satisfaction, pain control, and function. TEA-treated patients experienced similar rates of complications, length of stay, and mortality with no statistically or clinically significant increase in hypotensive episodes, transfusion, or renal insufficiency events. Moreover, the pain control experience associated with TEA was superior, particularly during the first 48 hours after surgery. Although not specifically addressing pain level at rest in comparison to during activity, this methodology did include simultaneous evaluation of pain level and function. Ultimately, the primary endpoint was confirmed on 4 scales, including AUC of pain scores, severe pain event rates, total narcotic usage, and patient-reported outcomes of satisfaction with pain control and function.
Several areas of the study require specific commentary. First, the randomization strategy was 2.5 TEA to 1 IV-PCA entrant. The rationale for this methodology was to simultaneously have the statistical power to comment on the primary endpoint of AUC 48, and to comment on potential TEA-related anesthetic complications, including hypotension, transfusion, and renal insufficiency. By weighting the accrual toward the TEA group the study was able to determine that the TEA was both effective and safe.
Second, with specific regard to the TEA regimen, the study used a strict protocol for drug concentration, infusion, and boluses. The concentration of local anesthetic was 0.075% bupivacaine, a concentration that is lower than typically reported. Using this lower concentration and a regimented rescue bolus regimen, study patients achieved excellent pain control, while avoiding hypotension and other commonly reported anesthetic complications that have been associated with TEA catheters. The data, therefore, support a reevaluation of prior studies that found excessive rates of hypotension and/ or fluid resuscitation in the absence of reporting epidural concentration data, variability in concentration and drug choice, or higher concentrations of local anesthetic. 28 Third, within the literature on this topic the present study uniquely included patient-reported outcomes data in addition to patient-reported pain scores. These data are important because they confirm that the patient satisfaction and experience associated with improved pain scores was superior in the TEA group. Furthermore, the patient function in the TEA group was superior to the IV-PCA group. This finding is related not only to lower pain levels and less concomitant anxiety, but also to the almost 3-fold reduction in narcotic usage in the TEA group.
This reduction in IV and enteral narcotics is important, as the United States grapples with a significant narcotic dependence that is frequently initiated during a procedure or surgery. 46 Furthermore, in oncologic care there is emerging data that many cancers have high levels of mu opioid receptor expression, 47, 48 that when activated by opiate narcotics could potentially mediate tumor growth and spread. 49, 50 As more is learned about the interaction between these receptors and perioperative narcotics, it may become imperative that oncologic surgeons seek alternative methods to reduce perioperative opioid delivery. This trial supports that TEA is a safe and effective tool for limiting opiate narcotic dosing.
Fourth, like any randomized trial, global progress in the field does not wait for published results. During the course of this study, enhanced recovery and transversus abdominis plane (TAP) block have emerged as advances in multiple areas of surgical care. Although the present study was pathway driven with a modern protocol containing several progressive elements common to enhanced recovery (e.g., minimization of tubes and drains), specific oral nonopioid analgesic agents common to many enhanced recovery pathways were not given. Regarding, more traditional adjuvant agents, such as acetaminophen and ketorolac, the distribution of use was equivalent in each group.
Lastly, it is clear that minimally invasive approaches provide pain and experience advantages to patients. A recent national audit of 2015 to 2016 activity, however, found that the vast majority of liver resections (84%) continue to be done through open approaches, with a higher penetrance of minimally invasive approaches in minor liver resection (78%), compared to major liver resection (95%) (unpublished ACS-NSQIP HPB collaborative data courtesy of Dr Henry Pitt). Although each of these recent trends was not included in this trial, the results validate the shared concepts of the trial, which This is a refreshing study because it deals with reducing morbidity of open incisions. In recent years, surgeons have focused appropriately on minimally invasive techniques. For medium-size operations, such as laparoscopic cholecystectomy and hiatal hernia surgery in which the incision is the major source of morbidity, there is no doubt about the superiority of minially invasive surgery (MIS). For large abdominal operations in which the incision is, however, often not the main source of morbidity, the benefit of MIS seems less clear. For instance, in operations for rectal cancers, 2 excellent randomized control trials found that oncologic results of the MIS approach are not equal to that of the open operation, despite prior nonrandomized trials having concluded the opposite.
Therefore, it is now especially important to find novel ways to reduce the morbidity of open incisions, to lessen the occurrence of wound infections, pulmonary consequences, postoperative hernias, and, as in this article, to reduce postoperative pain.
Epidural anesthesia sometimes causes hypotension and the undesirable need for pressors or infusions of isotonic electrolyte solutions. By modulating the doses of local anesthetics and narcotics, the authors have cleverly managed to avoid this problem. This will encourage many epidural nonbelievers, like myself, to give this method another chance.
The 2.5 to 1 randomization is understandable, but unusual, and resulted in a very small control group of 34 patients. This means that study observations must be highly standardized for the results to be convincing. In this regard, what steps were taken to assure that pain scores were obtained at times that eliminated the effect of activities such as walking or coughing? Did the authors consider taking pain scores at rest and with activity?
The use of nonnarcotic medications could have important effect on results. Was their use in the 2 groups measured, and was it equivalent?
In 2012, Reavie and others from the Royal Infirmary in Edinburgh concluded in a randomized trial that local anesthetic wound infiltration, combined with patient-controlled opiate analgesia, reduced length of stay compared with epidural analgesia after open liver resection. Epidural analgesia provided superior analgesia, but it did not confer benefits in terms of faster mobilization.
A number of techniques using local anesthesia such as local wound infiltration, TAP block, and epidural anesthesia are now available. How do the authors propose that this be sorted out? Is there a need for multicenter trials with many hundreds, if not thousands of patients, to have the power to do so? Thank you.
Dr Thomas A. Aloia (Houston, TX):
Thank you, Dr Strasberg, for those comments. Regarding the randomization and the standardization in that arm, I think what was borne out in the study was something that's intuitive in that we know how patients react to PCA narcotics. We have had such a long experience that actually their reaction and their complications and their issues were very representative. And, the IQR of outcomes within the PCA group is fairly tight, justifying the 1:2.5 randomization.
You make an excellent point about other adjuvant agents that I would like to address. We have gone back to all of the patients in the database. If we look at the 2 most common adjuvant agents being acetaminophen and ketorolac, they were equally distributed in both groups. Now, during the course of the present study, enhanced recovery in liver surgery has really taken off, and it has in our group. We intentionally did not implement an enhanced recovery pathway during the study to make this equivalent, but we did have a standardized postoperative order set during the entire time for both sets of patients. So the only real omissions from an enhanced recovery pathway are we did not carbo-load these patients and we did not use premedications of pregabalin and celecoxib as we would now.
Regarding the study from Professor Garden's group, I think it was a very interesting study pairing a wound infiltration technique with PCA. And I would say that they are actually corollary in that I think our study puts a nail in the coffin of PCA alone. So any adjuvant agent we can bring on board that lowers the rate of intravenous narcotics is likely to be beneficial to our patients.
I will point out, though, a difference between, say, TAP block and epidural, which are really nerve blocks versus a wound infiltration, which was used mainly in that study, is that we are learning more about the inflammatory and oncologic benefits of a true nerve blockade that can only be brought by a spinal, a TAP, or an epidural. And so I think that the study to be done is that one, and to that end, we have opened our next randomized trial, which is TAP versus epidural with enhanced recovery in both arms for these same exact patients.
The last thing I would like to emphasize before other questions, to back up your point, I asked Dr Pitt to provide me with the NSQIP HPB collaborative data on how many patients today are undergoing open resections in liver surgery. And during 2015 to 2016, with 3300 patients in the registry, minor hepatectomy was performed 78% of the time with an open incision, and major hepatectomy was performed 95% with an open incision.
So it's not to say that we should not increase our use of minimally invasive approaches, but we would fully agree that we need to continue to explore optimal analgesia in open surgery.
Dr David Kooby (Atlanta, GA):
Tom, congratulations to you and your coauthors for taking a concept that was retrospective and turning it into a prospective study, running with it and getting it done. I have some comments and questions.
I think we must keep in mind certain realities. If you are working in 1 hospital with 1 anesthesia group that's focused on aesthetic management for major hepatectomy and HPB surgery, it is easier to apply a system such as you described. Our reality with 4 centers, 10 surgeons operating in a metropolitan area, coming from several different anesthesia groups is a little bit more difficult to manage, and we also do not know which anesthesiologist is going to be managing our case and, more importantly, which anesthesiologist or advanced practice provider is going to round on the floor to assess these patients postoperative outside of a clinical trial.
We have adapted a different approach. We have focused on aspects that surgical teams could control: things such as careful fluid management in the operating room, cautious pain management with agents such as acetaminophen (Tylenol), tramadol, ketorolac (Toradol), and then a TAP block. I think it comes down to having a management pathway.
Can you comment a little bit more about your patients who did not have epidurals? What was standard management? I did not see that in your presentation. Can you also comment a little bit more about pulmonary complications in the epidural group versus not? Dr Thomas A. Aloia (Houston, TX):
The pulmonary complication rate was low in both groups. I think the activity levels that were demonstrated at each given day, better in the epidural group than even in the PCA group, is likely attributable to that. What I would say about centers that do not feel comfortable or that it's not safe to be having an epidural in their environment, I would just ask to relook at the specifics of the epidural. And I do think that lowering the local concentration, which our anesthesiologist told us was going to completely ruin this trial because the patients were going to be in agony, was proven wrong, and that, indeed, our hypotensive events went way down.
And then the other thing is the 2 strike rule, that we suggest granting 2 chances to fix the epidural issues, via your resident at night or the pain team, and then surgery aggressively intervenes, and we did in these patients. But regardless of the results of this study, I think the main idea is a block is better than no block. And if in your environment that means a TAP or a one shot spinal or an epidural, those are all acceptable. Thank you, David.
Dr William Nealon (New York, NY):
I congratulate the group on a very interesting study. I have had a career long obsession with this issue. You have made 1 observation, which I discovered many years ago, which is bupivacaine is at the root of most of the negative aspects of an epidural, including the urinary retention, the numbness of the legs, and hypotension. Early in my career, the distribution of a narcotic and bupivacaine was individually matched. They then decided they could just make it automated, which resulted in an amount of bupivacaine that has a very high rate of sympathectomy. Thus the nightly routine is the intern gets called because the patient's blood pressure is low. They give between 2 and 4 L of crystalloid and at which point they realize it's the epidural. So they turn down the epidural and now the patient is in severe pain, and you come in the next morning and you have the outcome of fluid overload and the patient still in pain.
I have now moved several times in the last few years. I have to retrain anesthesia every time I move in this concept, and it's still not easy to demonstrate. This article will be key to stress the specific message that it is the bupivacaine that you need to modify. I don't think any of us would disagree that a really perfectly functioning epidural is far superior to any other type of postoperative anesthesia. Great article.
Dr Thomas A. Aloia (Houston, TX):
Just to note that the Dilaudid concentration, the narcotic in our epidural, was 5 mg/mL as well.
Dr Kim Olthoff (Philadelphia, PA):
I appreciated this article because we, as a transplant group in the A2ALL clinical trial living donor consortium struggled with the pain management in our living donors who routinely have 60% or 65% hepatic resections. We had a pain management work group look at this, and in our center, we actually got together our anesthesiologists and pain management team to revise our epidural management because we had 2 significant episodes of 1 respiratory decompensation and hypotension. Our donors actually now receive an even lower dose of 0.05% bupivacaine in our epidurals and a low dose of narcotics, with good results. We have tried both the PCA and the patient controlled epidural analgesia (PCEA), and prefer the PCEA. So I appreciate what you have shown here, and it actually just confirms what we have decided to do in our individual center.
My question to you is about the difficult time period in transition from the epidural to oral pain medicines. Have you found a difference between the PCA, the PCEA, and return of bowel function, and the control of pain management in that 48-to 72-hour time period? Dr Thomas A. Aloia (Houston, TX):
It's a great question. I think what we have learned about that is when we have a well-functioning epidural; we ride that as long as possible. It's interesting, even my Fellow yesterday said, ''Mr. Soand-So is doing great. On day two I want to cap his epidural.'' I said, ''No. That's exactly what we want. We want to get him eating a fully solid diet so the transition to pills is well-tolerated, and then you pull back the epidural.'' So to that point, we would fully agree.
And indeed, we have a very low Toradol use in the first 48 hours when the patients tend to be hypovolemic and on the rocks a little bit with the kidneys. Where we really like it is at that transition point between the epidural and oral medications. Most times 1 or 2 doses of Toradol can bridge and avoid a regression to IV narcotics when the epidural comes off.
Dr David Soybel (Hershey, PA):
I have a comment and a question. The comment is that with newer techniques and more detailed understanding of the abdominal wall anatomy that we are getting from experience in complex abdominal wall hernia repair, pain management can be actually owned by the surgeon. You can do your own TAP in the operating room. In our institution, we are seeing more consistent results. That leads to my question about variation in effectiveness between different cases. What if, instead of looking at the mean of pain management scores, you analyzed the percentage of patients achieve a pain level of 3 or less that allows them to get around and mobilize better? If you have looked at that in that way, what percentage of success do you have on any given day? You had 1 slide, I think, that sort of addressed that, but I just wondered what your thoughts were about that.
Dr Thomas A. Aloia (Houston, TX):
We do have data on that from this trial, but also our larger epidural experience. It tells us that 70% of our epidurals using this concentration are effective. We have 20% that get split for inadequate-semiadequate pain control. And what that means is we add a low-dose PCA to it. And then we have that 10% or 11% that are just a failure, and we immediately get off of them when we recognize that.
With regard to TAP and variability, I think it is important to actually be trained in placing the block and put it in the right place, but our data with even expert placed TAP is it's 70% effective, for about 2 full days. So I think we have to measure variability on all those modalities, and we hope that our next randomized trial, which directly compares those 2, can answer that question.
Dr Keith D. Lillemoe (Boston, MA):
Tom, if I could just as 1 quick question. I do not know if you have anesthesia trainees at MD Anderson, but we certainly do. Can you talk about the variability in on-time starts, how long it takes to place an epidural catheter, and how many epidurals actually were successfully placed that did not get aborted?
Dr Thomas A. Aloia (Houston, TX):
Inability to place the epidural is very low in our setting. We do have anesthesia trainees, both fellows and residents. Where I suggest that we found way more variability is that the pain service, staffed by an attending and APPs during the day, was beautiful at following these patients. But at night, the residents took over, and it was like a chemistry lab, and the boluses were all over the place. So we had to rein in the anesthesia trainees actually more in the postoperative setting than the intraoperative.
Dr Keith D. Lillemoe (Boston, MA):
How about on-time starts or length?
Certainly it takes time to place an epidural. We had our anesthesiologist starting to place the epidurals and even the A-lines in the preoperative holding in advance of the case, but I would also comment that a properly done TAP block under ultrasound guidance before incision takes 20 to 30 minutes as well. So there may be less difference with another type of block.
Dr Robert Cerfolio (Birmingham, AL):
I think the point you just made about variability is the key. High-functioning teams do well because they reduce variables-The Yankees, can I say that here in Philly, do not show up and ask who is playing shortstop today. They know who their shortstop is.
I am a thoracic surgeon at University of Alabama at Birmingham. We have eliminated epidurals 9 years ago. We eliminated PCAs 5 years ago. And if we can do thoracotomies without either-one of the more painful operations there is-then I think general surgeons can do most of theirs without them. We eliminated them because it is a different team member every day slows you down, adds risk and complications and then you add them to your team unnecessarily postoperatively. In this way, we reduce all these variables in these times, and we can control people's pain. Maybe 10% to 15% require a PCA outside of our protocols. I think that is the way to reduce cost, reduce delays, reduce variables, and get better outcomes. So even if you are not doing minimally invasive technique, we can do thoracotomies that spare the rib, the nerve, spare the muscle, and avoid IVanalgesia in approximately 80% of our patients.
Dr Thomas A. Aloia (Houston, TX):
I think that's to your point about a high-functioning team, because paravertebral blocks in open thoracic surgery are used by approximately 5% of total thoracic groups. So I think we are in parallel on that. And, obviously, a well-placed nerve block is really the key, so best outcomes are made with whatever your system can provide in that regard.
Dr Robert Cerfolio (Birmingham, AL):
Agreed, and we have eliminated pre-and postoperative blocks as well. When you put a scope in the chest, you can see your local with epi going in subpleurally so we do it at the time of surgery-and we do it right after the first incision pre-emptively and per os (PO) gabapentin and PO Tylenol in the holding area. Intra-op paravertebral block adds great value: they improve quality because they are 100% effective and patient is asleep and not awake, it also reduces cost and reduces variables-that is value.
